Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hyloris Pharmaceuticals SA ( (DE:52U) ) just unveiled an update.
Hyloris Pharmaceuticals announced positive results from a pivotal study of Dofetilide IV, an innovative intravenous formulation for treating atrial fibrillation and atrial flutter. The study supports a planned New Drug Application to the FDA, with potential to transform treatment by reducing hospital stays and healthcare costs, enhancing patient outcomes, and solidifying Hyloris’s position in the market.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating and optimizing existing medications to meet unmet medical needs. The company leverages established regulatory pathways to reduce development timelines and costs, with a portfolio of 21 reformulated and repurposed medicines.
YTD Price Performance: -27.17%
Average Trading Volume: 299
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €150.1M
For an in-depth examination of 52U stock, go to TipRanks’ Stock Analysis page.